Systematic review: microRNAs as potential biomarkers in mild cognitive impairment diagnosis
Author
dc.contributor.author
Ogonowski, Natalia
Author
dc.contributor.author
Salcidua, Stefanny
Author
dc.contributor.author
León Albarracín, Tomás
Author
dc.contributor.author
Chamorro Veloso, Nayaret
Author
dc.contributor.author
Valls, Cristian
Author
dc.contributor.author
Avalos, Constanza
Author
dc.contributor.author
Bisquertt, Alejandro
Author
dc.contributor.author
Rentería, Miguel E.
Author
dc.contributor.author
Orellana, Paulina
Author
dc.contributor.author
Duran Aniotz, Claudia
Admission date
dc.date.accessioned
2022-12-01T13:15:52Z
Available date
dc.date.available
2022-12-01T13:15:52Z
Publication date
dc.date.issued
2022
Cita de ítem
dc.identifier.citation
Frontiers in Aging Neuroscience January 2022 Volume 13 Article 807764
es_ES
Identifier
dc.identifier.other
10.3389/fnagi.2021.807764
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/189542
Abstract
dc.description.abstract
The rate of progression from Mild Cognitive Impairment (MCI) to Alzheimer's disease (AD) is estimated at > 10% per year, reaching up to 80-90% after 6 years. MCI is considered an indicator of early-stage AD. In this context, the diagnostic screening of MCI is crucial for detecting individuals at high risk of AD before they progress and manifest further severe symptoms. Typically, MCI has been determined using neuropsychological assessment tools such as the Montreal Cognitive Assessment (MoCA) or Mini-Mental Status Examination (MMSE). Unfortunately, other diagnostic methods are not available or are unable to identify MCI in its early stages. Therefore, identifying new biomarkers for MCI diagnosis and prognosis is a significant challenge. In this framework, miRNAs in serum, plasma, and other body fluids have emerged as a promising source of biomarkers for MCI and AD-related cognitive impairments. Interestingly, miRNAs can regulate several signaling pathways via multiple and diverse targets in response to pathophysiological stimuli. This systematic review aims to describe the current state of the art regarding AD-related target genes modulated by differentially expressed miRNAs in peripheral fluids samples in MCI subjects to identify potential miRNA biomarkers in the early stages of AD. We found 30 articles that described five miRNA expression profiles from peripheral fluid in MCI subjects, showing possible candidates for miRNA biomarkers that may be followed up as fluid biomarkers or therapeutic targets of early-stage AD. However, additional research is needed to validate these miRNAs and characterize the precise neuropathological mechanisms.
es_ES
Patrocinador
dc.description.sponsorship
Alzheimer's Association 2018-AARG-591107
ID20I10152
1210622
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT PIA/ANILLOS ACT210096
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
Frontiers Media
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States